Histogenics Corp (NASDAQ:HSGX) shares gapped up prior to trading on Monday . The stock had previously closed at $0.18, but opened at $0.19. Histogenics shares last traded at $0.19, with a volume of 23,939 shares trading hands.

Separately, ValuEngine upgraded shares of Histogenics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $2.44.

The company has a market cap of $19.96 million, a P/E ratio of -0.27 and a beta of 3.27. The firm’s 50 day moving average price is $0.19 and its 200-day moving average price is $0.17.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in shares of Histogenics in the fourth quarter valued at about $25,000. Virtu Financial LLC boosted its position in shares of Histogenics by 505.8% in the first quarter. Virtu Financial LLC now owns 592,976 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 495,096 shares during the period. Finally, CVI Holdings LLC bought a new stake in shares of Histogenics in the second quarter valued at about $6,541,000. 11.02% of the stock is currently owned by institutional investors.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Further Reading: CD Ladder

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.